AgomAb Therapeutics (Public limited company)
AgomAb Therapeutics is a Belgian company registered with the Crossroads Bank for Enterprises under enterprise number 0674.527.310. It was founded on 13-04-2017. Its registered office is in Antwerp. Its main activity is: Architectural and engineering activities; technical testing and analysis. Its annual accounts for 2025 report equity of € 244 064 213 and a loss of € 9 622 983. These accounts report 52 full-time equivalents. Addrly gives it a financial health grade of A, on a scale from A (safest) to E (most at risk). It filed its annual accounts within the legal deadline for each of its last 4 financial years.
Information last updated on 14-10-2026.
Company information
Key figures of AgomAb Therapeutics
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
Profit / lossiWhat the period earned after taxes. A negative amount is a loss. | € -9 622 983+18 % | € -11 716 884-39 % | € -8 440 501+10 % | € -9 396 576 |
EquityiWhat belongs to the shareholders: capital contributed, reserves and profits kept in the company. | € 244 064 213-4 % | € 253 687 197+38 % | € 183 349 854+89 % | € 96 919 958 |
Total assetsiEverything the company owns. Equal to total equity and liabilities, which says how it is financed. | € 251 330 496-3 % | € 258 662 264+37 % | € 188 731 357+86 % | € 101 289 830 |
Gross marginiSales and other operating income, minus purchases of goods and services. What is left to pay the staff and everything else. | - | € 3 962 010+168 % | € 1 477 010+49 % | € 993 210 |
Employees (FTE)iAverage number of workers over the period, in full-time equivalents. | 52+27 % | 40.9+111 % | 19.4+92 % | 10.1 |
Financial estimate
- 1 Shareholders
Similar companies
Other companies in the same activity in Antwerp.
| Company | Town |
|---|---|
| Normec Planning | 2600 Antwerpen |
| ANTEA BELGIUM | 2600 Antwerpen |
| WITTEVEEN+BOS BELGIUM | 2600 Antwerpen |
| SMAK ARCHITECTS | 2600 Antwerpen |
| Edm. J.M. Mertens en Compagnie | 2600 Antwerpen |
| SOPEX COMMODITY SOLUTIONS | 2600 Antwerpen |
| STUDIEBUREEL A.S.E. | 2600 Antwerpen |
| BLADT BUILDING ENGINEERING | 2600 Antwerpen |
Frequently asked questions
Is AgomAb Therapeutics still active? Yes. The Crossroads Bank for Enterprises lists AgomAb Therapeutics as active.
What is the VAT number of AgomAb Therapeutics? The VAT number of AgomAb Therapeutics is BE 0674.527.310.
When was AgomAb Therapeutics founded? AgomAb Therapeutics was founded on 13-04-2017.
What is the address of AgomAb Therapeutics? The current registered office of AgomAb Therapeutics is Posthoflei 1, 2600 Anvers.
When did AgomAb Therapeutics last file annual accounts? The latest annual accounts of AgomAb Therapeutics were filed on 23-06-2026.
Does AgomAb Therapeutics file its annual accounts on time? Yes. AgomAb Therapeutics filed its annual accounts within the legal deadline for each of its last 4 financial years.
How many employees does AgomAb Therapeutics have? AgomAb Therapeutics employs 52 full-time equivalents according to its most recent annual accounts.
Is AgomAb Therapeutics financially healthy? Addrly gives AgomAb Therapeutics a financial health grade of A, on a scale from A (safest) to E (most at risk). The failure probability and the indicators behind it are visible with a free account.
Is AgomAb Therapeutics profitable? The annual accounts of AgomAb Therapeutics for 2025 show a loss of € 9 622 983.
What is the equity of AgomAb Therapeutics? The equity of AgomAb Therapeutics was € 244 064 213 at the close of the 2025 financial year.
Who are the directors of AgomAb Therapeutics? The annual accounts of AgomAb Therapeutics record 15 mandates. The names, roles and dates are visible with a free account.
Can AgomAb Therapeutics receive Peppol e-invoices? Yes. AgomAb Therapeutics is registered on the Peppol network and can receive structured electronic invoices.
What does AgomAb Therapeutics do? The main activity of AgomAb Therapeutics is: Architectural and engineering activities; technical testing and analysis.